United States, 27 January 2026, The Medicines and Healthcare products Regulatory Agency (MHRA) has formally published new guidance and a suite of online resources focused on the use of digital mental health technologies (DMHT). Developed in partnership with NHS England’s MindEd programme and funded by Wellcome, these resources aim to help the public, clinicians, and educators distinguish between general wellbeing tools and regulated medical devices classification.
As the use of symptom-tracking apps and virtual reality therapies grows, the MHRA is emphasizing that digital tools are not replacements for professional healthcare but should be built on reliable evidence and clear safety standards.
DIGITAL MENTAL HEALTH TECHNOLOGIES KEY REQUIREMENTS FOR MANUFACTURERS
The new guidance clarifies the expectations for developers and manufacturers operating in the UK market. The MHRA guidance outlines five critical areas that impact how products are classified and marketed:
- Medical Purpose and Classification: If a digital tool claims to diagnose, treat, or manage a mental health condition, it is classed as a medical device classification. Manufacturers must ensure these claims are supported by medical evidence and clearly explained.
- Evidence of Efficacy: Trustworthy products are now expected to provide transparent information on how they have been tested or evaluated, such as through clinical studies. Developers should avoid “big promises” that lack supporting technical data.
- User Specification: Manufacturers must clearly state the intended user base. Tools designed for adults are often not suitable for children or teenagers; age appropriateness must be explicit.
- Safety Marking and Registration: Regulated digital mental health tools must meet UK safety standards and display a CE or UKCA mark. Manufacturers are required to register these products on the MHRA’s online public register.
REGULATORY & REPORTING FRAMEWORK
The MHRA guidance and NICE are moving toward a more “proportionate regulation” model to keep pace with fast-moving digital innovation.
- The Yellow Card Scheme: Users and professionals are being encouraged to report any regulated technology that causes harm or distress through the Yellow Card scheme. Manufacturers must be prepared for post-market surveillance and potential regulatory action based on these reports.
- Expansion of NICE Appraisals: Under the government’s 10-Year Health Plan, NICE is expanding its technology appraisal process to include digital products, diagnostics, and devices for the first time. This ensures that innovation is matched by rigorous evaluation.
- Data Protection: Manufacturers must ensure that sensitive personal information is handled transparently, with easily accessible information on how data is stored and utilized.
RESOURCES
To help manufacturers and stakeholders navigate these requirements, the following resources are available:
- MindEd Digital Mental Health Programme: Full resources for the public and professionals.
- MHRA Public Register: Check registered medical device Classification.
- Yellow Card Scheme: Report safety concerns.
- Digital Mental Health Technology Collection: Guidance on safe use and regulation.